What is Mesenbio?
Mesenbio is a specialized biopharmaceutical entity originating from the University of York, dedicated to the advancement of extracellular vesicle (EV) therapeutics. At the core of its operations is the proprietary Cell Line Extracellular Vesicle Release (CLEVR) platform. This technology is engineered to resolve the industry-wide challenge of consistency in EV production, which has historically hindered the scalability of such treatments. By facilitating an endless supply of high-quality, therapeutically active extracellular vesicles, Mesenbio is effectively positioning itself as a leader in the next generation of medical modalities. The company's focus remains on unlocking the potential of these biological particles to treat a diverse range of conditions, thereby bridging the gap between laboratory discovery and clinical application.
How much funding has Mesenbio raised?
Mesenbio has raised a total of $1.8M across 1 funding round:
Other Financing Round
$1.8M
Other Financing Round (2024): $1.8M with participation from NG Bio
Key Investors in Mesenbio
NG Bio
NG Bio Ltd is a specialized investment entity focused on breakthrough cures for chronic diseases, operating as an appointed representative of Midmar Capital LLP. The firm provides strategic backing to innovative healthcare ventures, emphasizing the advancement of medical research and the improvement of patient outcomes.
What's next for Mesenbio?
With the recent capital infusion, Mesenbio is poised to intensify its research and development efforts, specifically targeting the optimization of its CLEVR platform for broader therapeutic applications. The strategic roadmap involves expanding the company's pipeline and refining manufacturing processes to meet rigorous regulatory standards. As the firm moves deeper into the preclinical stage, the focus will shift toward establishing key partnerships and validating the efficacy of its EV-based treatments in more complex models. This phase of growth is critical for the company as it seeks to transform the landscape of regenerative medicine and establish a sustainable, long-term presence in the global biopharmaceutical market.
See full Mesenbio company page
